Effects of aPL antibodies and control antibodies on renal histology and function
Ab . | ↑ glomerular deposition/expression . | EM . | Thrombin generation and renal function . | Amelioration of GEC injury and renal failure . | ||||||
---|---|---|---|---|---|---|---|---|---|---|
C3 . | Fibrin . | TF . | GEC damage . | ↑TAT . | ↑BUN . | ↑ACR . | C5aR−/− mice . | Low TF mice . | Pravastatin . | |
FB1 (C′ activating Ab) | Yes | Yes | Yes | Yes | Yes | Yes | Yes | Yes | Yes | Yes |
FC1 (anti-B2GPI Ab) | No | No | No | Yes | Yes | Yes | Yes | No | Yes | Yes |
FD1 | No | No | No | No | No | No | No | NA | NA | NA |
aPL-IgG | Yes | Yes | Yes | No | Yes | Yes | Yes | Partial | Yes | Yes |
NH-IgG | No | No | No | No | No | No | No | NA | NA | NA |
Ab . | ↑ glomerular deposition/expression . | EM . | Thrombin generation and renal function . | Amelioration of GEC injury and renal failure . | ||||||
---|---|---|---|---|---|---|---|---|---|---|
C3 . | Fibrin . | TF . | GEC damage . | ↑TAT . | ↑BUN . | ↑ACR . | C5aR−/− mice . | Low TF mice . | Pravastatin . | |
FB1 (C′ activating Ab) | Yes | Yes | Yes | Yes | Yes | Yes | Yes | Yes | Yes | Yes |
FC1 (anti-B2GPI Ab) | No | No | No | Yes | Yes | Yes | Yes | No | Yes | Yes |
FD1 | No | No | No | No | No | No | No | NA | NA | NA |
aPL-IgG | Yes | Yes | Yes | No | Yes | Yes | Yes | Partial | Yes | Yes |
NH-IgG | No | No | No | No | No | No | No | NA | NA | NA |
Effects of FC1, FB1, FD1, aPL-IgG, and NH-IgG on glomerular C3 and fibrin deposition, TF expression and synthesis, plasma thrombin antithrombin III (TAT) levels, and renal function (BUN and ACR). The last 3 columns represent the effect of genetic deletion of C5aR, genetic diminution of TF, and pravastatin treatment on endothelial injury and renal failure.
C′ indicates complement; Ab, antibody; GEC, glomerular endothelial cell; and NA, not applicable.